Dr. Reddy’s Laboratories has received an Establishment Inspection Report (EIR) for its Formulation Srikakulam Plant (SEZ) Unit II, Andhra Pradesh from the US Food and Drug Administration (USFDA).
Recently, USFDA had completed the inspection at Dr. Reddy’s API Mirfield Plant, United Kingdom on September 15, 2017. The company had been issued a Form 483 with three observations.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
